Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia

  • Srinivas Vinod Saladi
  • , Swati Garg
  • , Ellen L. Weisberg
  • , Abigail E. Case
  • , Wei Ni
  • , Siddhika Pareek
  • , Klaus Podar
  • , Ravi Salgia
  • , James D. Griffin
  • , Richard M. Stone
  • , Martin Sattler

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

Abstract

Acute myeloid leukemia (AML) is characterized by poor survival, especially in older patients with relapse/refractory disease. With an apparent lack of reliable long-term treatments, pathways involved in chromatin regulation represent potentially leverageable targets. The arginine methyltransferase CARM1 is a known dependency in AML, yet clinical grade inhibitors have remained elusive. We found that CARM1 promotes DNA repair and other pathways associated with malignant growth. Dysregulation of DNA repair pathways is pervasive in AML and linked to the transforming phenotype. Interestingly, targeting CARM1 chemosensitized AML cells for DNA-PK inhibition by peposertib, thereby blocking NHEJ (non-homologous end joining). Also, H3K27ac (histone H3 lysine 27 acetylation) active enhancer marks and marks of the corresponding histone acetyltransferase, P300, were found at the promoter region of relevant CARM1-regulated DNA repair enzymes. Consequently, our results show that CARM1 dependencies could also be exploited by utilizing inobrodib, a p300/CBP bromodomain inhibitor that synergizes with peposertib treatment in AML cells. Overall, these data demonstrate a rational approach for combination therapy by exploiting dependencies through inhibition of proximal effector function in addition to essential NHEJ repair, targeting its rate-limiting enzyme complex, thereby resulting in synergistic inhibition in primary AML.

OriginalspracheEnglisch
Aufsatznummer201262
Seiten (von - bis)201262
FachzeitschriftMolecular Therapy Oncology
Jahrgang34
Ausgabenummer3
DOIs
PublikationsstatusVeröffentlicht - 17 Sept. 2026

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gute Gesundheit und Wohlergehen
    SDG 3 – Gute Gesundheit und Wohlergehen

Fingerprint

Untersuchen Sie die Forschungsthemen von „A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren